CNTX ▲ +2.7% - Context Therapeutics Inc. $CNTX - Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 Context Therapeutics rose 2.7% after announcing it has dosed the first patient in a Phase 1 trial of its experimental drug CT-202, marking a clinical milestone for the company's development program. 09-SEP-2026 07:30 AM ET